title: IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
abstract: Despite the appearance of the direct acting antiviral drugs, pegylated interferon/ribavirin (PEG-IFN/RBV) still has a place in the standard of care (SOC) therapy for chronic HCV4. Studies were conducted to find an accurate prediction in response to SOC therapy. Pretreatment serum interferon-γ-inducible protein-10 (IP-10) is an independent predictive factor of sustained virological response (SVR) in HCV1-infected patients. To assess whether the pretreatment serum level of IP-10 influences hepatic fibrosis and PEG-IFN/RBV therapy response, a study was conducted on 88 chronic Hepatitis C virus (HCV) patients who received PEG-IFN/RBV. Patients were subjected to a pretreatment routine laboratory evaluation, liver biopsy, and serum IP-10 assessment. They were followed up for 6 months after cessation of therapy (week 72). Patients were classified into 3 groups according to their response; nonresponders, relapsers, or sustained virological responders. The relation of pretreatment IP-10 with fibrosis and response was assessed. The studied groups were matched regarding their demographic data. There was no statistically significant association between the pretreatment IP-10 level and fibrosis (P=0.86) and no relation to response was found at week 12, 24, 48, and 72 (P=0.58, 0.8, 0.47, and 0.43, respectively). Pretreatment IP-10 could not predict either fibrosis or response to PEG-IFN/RIB therapy in chronic HCV Egyptian patients.
authors.affiliation: 1 Department of Endemic Hepatology and Gasteroenterology, Cairo University , Cairo, Egypt .
authors.forename: Maissa
authors.initials: M
authors.lastname: El Raziky
authors.affiliation: 1 Department of Endemic Hepatology and Gasteroenterology, Cairo University , Cairo, Egypt .
authors.forename: Aisha
authors.initials: A
authors.lastname: Elsharkawy
authors.affiliation: 2 Department of Biochemistry, Cairo University , Cairo, Egypt .
authors.forename: Salma E
authors.initials: SE
authors.lastname: Said
authors.affiliation: 3 Department of Chemical and Clinical Pathology, Faculty of Medicine, Cairo University , Cairo, Egypt .
authors.forename: Sahar
authors.initials: S
authors.lastname: Abdelatty
authors.affiliation: 1 Department of Endemic Hepatology and Gasteroenterology, Cairo University , Cairo, Egypt .
authors.forename: Wafaa
authors.initials: W
authors.lastname: El Akel
authors.affiliation: 1 Department of Endemic Hepatology and Gasteroenterology, Cairo University , Cairo, Egypt .
authors.forename: Omnia
authors.initials: O
authors.lastname: Tantawy
authors.affiliation: 1 Department of Endemic Hepatology and Gasteroenterology, Cairo University , Cairo, Egypt .
authors.forename: Hadeel
authors.initials: H
authors.lastname: Gamal Eldeen
authors.affiliation: 1 Department of Endemic Hepatology and Gasteroenterology, Cairo University , Cairo, Egypt .
authors.forename: Mahasen
authors.initials: M
authors.lastname: Mabrouk
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D054357:Chemokine CXCL10 / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000209:etiology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012372:ROC Curve; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D054357:Chemokine CXCL10; D016898:Interferon-alpha; D012254:Ribavirin